Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

NLRP6 Deficiency in CD4 T Cells Decreases T Cell Survival Associated with Increased Cell Death.

Radulovic K, Ayata CK, Mak'Anyengo R, Lechner K, Wuggenig P, Kaya B, Hruz P, Gomez de Agüero M, Broz P, Weigmann B, Niess JH.

J Immunol. 2019 Jul 15;203(2):544-556. doi: 10.4049/jimmunol.1800938. Epub 2019 May 31.

PMID:
31152078
2.

Metabolite-Sensing G Protein-Coupled Receptors Connect the Diet-Microbiota-Metabolites Axis to Inflammatory Bowel Disease.

Melhem H, Kaya B, Ayata CK, Hruz P, Niess JH.

Cells. 2019 May 14;8(5). pii: E450. doi: 10.3390/cells8050450. Review.

3.

Identification of druggable small molecule antagonists of the Plasmodium falciparum hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineering.

Heitmeier MR, Hresko RC, Edwards RL, Prinsen MJ, Ilagan MXG, Odom John AR, Hruz PW.

PLoS One. 2019 May 9;14(5):e0216457. doi: 10.1371/journal.pone.0216457. eCollection 2019.

4.

Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab.

Grandinetti T, Biedermann L, Bussmann C, Straumann A, Hruz P.

Dig Dis Sci. 2019 Aug;64(8):2231-2241. doi: 10.1007/s10620-019-05617-3. Epub 2019 Apr 13.

PMID:
30982212
5.

[The Role of the Exposome in the Emergence of Chronic Inflammatory Bowel Diseases].

Niess JH, Kaymak T, Hruz P.

Ther Umsch. 2019 Jan;75(5):261-270. doi: 10.1024/0040-5930/a000998. Review. German.

PMID:
30700238
6.

β6 -integrin serves as a novel serum tumor marker for colorectal carcinoma.

Bengs S, Becker E, Busenhart P, Spalinger MR, Raselli T, Kasper S, Lang S, Atrott K, Mamie C, Vavricka SR, von Boehmer L, Knuth A, Tuomisto A, Mäkinen MJ, Hruz P, Turina M, Rickenbacher A, Petrowsky H, Weber A, Frei P, Halama M, Jenkins G, Sheppard D, Croner RS, Christoph J, Britzen-Laurent N, Naschberger E, Schellerer V, Stürzl M, Fried M, Rogler G, Scharl M.

Int J Cancer. 2019 Aug 1;145(3):678-685. doi: 10.1002/ijc.32137. Epub 2019 Jan 29.

PMID:
30653264
7.

High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis.

Fuchs S, Sawas N, Staedler N, Schubert DA, D'Andrea A, Zeiser R, Piali L, Hruz P, Frei AP.

Eur J Immunol. 2019 Mar;49(3):462-475. doi: 10.1002/eji.201847862. Epub 2019 Jan 9.

PMID:
30578679
8.

Letter to the Editor: "Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline".

Laidlaw MK, Van Meter QL, Hruz PW, Van Mol A, Malone WJ.

J Clin Endocrinol Metab. 2019 Mar 1;104(3):686-687. doi: 10.1210/jc.2018-01925. No abstract available.

PMID:
30476120
9.

Contribution of systemic inflammation to permanence of KATP-induced neonatal diabetes in mice.

Emfinger CH, Yan Z, Welscher A, Hung P, McAllister W, Hruz PW, Nichols CG, Remedi MS.

Am J Physiol Endocrinol Metab. 2018 Dec 1;315(6):E1121-E1132. doi: 10.1152/ajpendo.00137.2018. Epub 2018 Sep 18.

PMID:
30226997
10.

High Prevalence of Vitamin D Deficiency among Patients with Inflammatory Bowel Disease.

Caviezel D, Maissen S, Niess JH, Kiss C, Hruz P.

Inflamm Intest Dis. 2018 Jul;2(4):200-210. doi: 10.1159/000489010. Epub 2018 Jun 28.

11.

Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn's Disease Patients.

Kaymak T, Moriconi F, Niess JH, Beglinger C, Hruz P.

Inflamm Intest Dis. 2018 Mar;2(3):171-179. doi: 10.1159/000486676. Epub 2018 Feb 21.

12.

Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS).

Safroneeva E, Saner C, Rossel JB, Golay D, Pittet V, Godat S, Diem S, Aepli P, Sawatzki M, Borovicka J, Burgmann K, Juillerat P, Netzer P, Sendensky A, Hruz P, Girardin M, Biedermann L, Greuter T, Vavricka S, Michetti P, Mueller C, Straumann A, Schoepfer AM; Swiss EoE Cohort Study Group.

Inflamm Intest Dis. 2018 Mar;2(3):163-170. doi: 10.1159/000486131. Epub 2018 Jan 31.

13.

TFEB-dependent induction of thermogenesis by the hepatocyte SLC2A inhibitor trehalose.

Zhang Y, Higgins CB, Mayer AL, Mysorekar IU, Razani B, Graham MJ, Hruz PW, DeBosch BJ.

Autophagy. 2018;14(11):1959-1975. doi: 10.1080/15548627.2018.1493044. Epub 2018 Aug 6.

14.

The Interleukin-20 Cytokines in Intestinal Diseases.

Niess JH, Hruz P, Kaymak T.

Front Immunol. 2018 Jun 18;9:1373. doi: 10.3389/fimmu.2018.01373. eCollection 2018. Review.

15.

Modulation of bacterial metabolism by the microenvironment controls MAIT cell stimulation.

Schmaler M, Colone A, Spagnuolo J, Zimmermann M, Lepore M, Kalinichenko A, Bhatia S, Cottier F, Rutishauser T, Pavelka N, Egli A, Azzali E, Pieroni M, Costantino G, Hruz P, Sauer U, Mori L, De Libero G.

Mucosal Immunol. 2018 Jul;11(4):1060-1070. doi: 10.1038/s41385-018-0020-9. Epub 2018 May 9.

PMID:
29743612
16.

Metabolic and Cardiac Adaptation to Chronic Pharmacologic Blockade of Facilitative Glucose Transport in Murine Dilated Cardiomyopathy and Myocardial Ischemia.

Heitmeier MR, Payne MA, Weinheimer C, Kovacs A, Hresko RC, Jay PY, Hruz PW.

Sci Rep. 2018 Apr 24;8(1):6475. doi: 10.1038/s41598-018-24867-1.

17.

Evaluating the Efficacy of GLUT Inhibitors Using a Seahorse Extracellular Flux Analyzer.

Wei C, Heitmeier M, Hruz PW, Shanmugam M.

Methods Mol Biol. 2018;1713:69-75. doi: 10.1007/978-1-4939-7507-5_6.

PMID:
29218518
18.

The Stimulation of Macrophages with TLR Ligands Supports Increased IL-19 Expression in Inflammatory Bowel Disease Patients and in Colitis Models.

Steinert A, Linas I, Kaya B, Ibrahim M, Schlitzer A, Hruz P, Radulovic K, Terracciano L, Macpherson AJ, Niess JH.

J Immunol. 2017 Oct 1;199(7):2570-2584. doi: 10.4049/jimmunol.1700350. Epub 2017 Sep 1.

19.

Development of GLUT4-selective antagonists for multiple myeloma therapy.

Wei C, Bajpai R, Sharma H, Heitmeier M, Jain AD, Matulis SM, Nooka AK, Mishra RK, Hruz PW, Schiltz GE, Shanmugam M.

Eur J Med Chem. 2017 Oct 20;139:573-586. doi: 10.1016/j.ejmech.2017.08.029. Epub 2017 Aug 14.

20.

MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis.

Edwards RL, Brothers RC, Wang X, Maron MI, Ziniel PD, Tsang PS, Kraft TE, Hruz PW, Williamson KC, Dowd CS, John ARO.

Sci Rep. 2017 Aug 21;7(1):8400. doi: 10.1038/s41598-017-07159-y.

21.

SLC2A8 (GLUT8) is a mammalian trehalose transporter required for trehalose-induced autophagy.

Mayer AL, Higgins CB, Heitmeier MR, Kraft TE, Qian X, Crowley JR, Hyrc KL, Beatty WL, Yarasheski KE, Hruz PW, DeBosch BJ.

Sci Rep. 2016 Dec 6;6:38586. doi: 10.1038/srep38586.

22.

Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis.

Navarini AA, Hruz P, Berger CT, Hou TZ, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg Sgier BC, Kämpe O, Burgener AV, Marquardsen F, Baldin F, Bigler M, Kistner A, Jauch A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker LT, Heijnen I, Daikeler TD, Gebbers JO, Grimbacher B, Sansom DM, Jeker R, Hess C, Recher M.

J Allergy Clin Immunol. 2017 Mar;139(3):1043-1046.e5. doi: 10.1016/j.jaci.2016.08.042. Epub 2016 Nov 28. No abstract available.

PMID:
27908448
23.

A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters.

Kraft TE, Heitmeier MR, Putanko M, Edwards RL, Ilagan MX, Payne MA, Autry JM, Thomas DD, Odom AR, Hruz PW.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7407-7414. Print 2016 Dec.

24.

Mammalian Glucose Transporter Activity Is Dependent upon Anionic and Conical Phospholipids.

Hresko RC, Kraft TE, Quigley A, Carpenter EP, Hruz PW.

J Biol Chem. 2016 Aug 12;291(33):17271-82. doi: 10.1074/jbc.M116.730168. Epub 2016 Jun 14.

25.

A new eosinophilic esophagitis (EoE)-like disease without tissue eosinophilia found in EoE families.

Straumann A, Blanchard C, Radonjic-Hoesli S, Bussmann Ch, Hruz P, Safroneeva E, Simon D, Schoepfer AM, Simon HU.

Allergy. 2016 Jun;71(6):889-900. doi: 10.1111/all.12879. Epub 2016 Apr 1.

PMID:
26970242
26.

Trehalose inhibits solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis.

DeBosch BJ, Heitmeier MR, Mayer AL, Higgins CB, Crowley JR, Kraft TE, Chi M, Newberry EP, Chen Z, Finck BN, Davidson NO, Yarasheski KE, Hruz PW, Moley KH.

Sci Signal. 2016 Feb 23;9(416):ra21. doi: 10.1126/scisignal.aac5472.

27.

Commentary.

Hruz PW.

Clin Chem. 2015 Dec;61(12):1444. doi: 10.1373/clinchem.2015.243964. No abstract available.

28.

Expression, purification, and functional characterization of the insulin-responsive facilitative glucose transporter GLUT4.

Kraft TE, Hresko RC, Hruz PW.

Protein Sci. 2015 Dec;24(12):2008-19. doi: 10.1002/pro.2812. Epub 2015 Oct 14.

29.

The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir.

Kraft TE, Armstrong C, Heitmeier MR, Odom AR, Hruz PW.

Antimicrob Agents Chemother. 2015 Oct;59(10):6203-9. doi: 10.1128/AAC.00899-15. Epub 2015 Jul 27.

30.

In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy.

Mishra RK, Wei C, Hresko RC, Bajpai R, Heitmeier M, Matulis SM, Nooka AK, Rosen ST, Hruz PW, Schiltz GE, Shanmugam M.

J Biol Chem. 2015 Jun 5;290(23):14441-53. doi: 10.1074/jbc.M114.628826. Epub 2015 Apr 6.

31.

A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis.

Miehlke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Bajbouj M, Schlag C, Madisch A, Fibbe C, Wittenburg H, Allescher HD, Reinshagen M, Schubert S, Tack J, Müller M, Krummenerl P, Arts J, Mueller R, Dilger K, Greinwald R, Straumann A.

Gut. 2016 Mar;65(3):390-9. doi: 10.1136/gutjnl-2014-308815. Epub 2015 Mar 19.

32.

Exercise-induced chest pain: an atypical manifestation of eosinophilic esophagitis.

Kahn J, Bussmann C, Beglinger C, Straumann A, Hruz P.

Am J Med. 2015 Feb;128(2):196-9. doi: 10.1016/j.amjmed.2014.08.007. Epub 2014 Sep 23.

PMID:
25261012
33.

HIV and endocrine disorders.

Hruz PW.

Endocrinol Metab Clin North Am. 2014 Sep;43(3):xvii-xviii. doi: 10.1016/j.ecl.2014.07.001. No abstract available.

PMID:
25169571
34.

Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease.

Mecklenburg I, Reznik D, Fasler-Kan E, Drewe J, Beglinger C, Hruz P; Swiss IBD Cohort Study Group.

J Crohns Colitis. 2014 Nov;8(11):1392-7. doi: 10.1016/j.crohns.2014.04.008. Epub 2014 May 11.

PMID:
24825446
35.

Isoform-selective inhibition of facilitative glucose transporters: elucidation of the molecular mechanism of HIV protease inhibitor binding.

Hresko RC, Kraft TE, Tzekov A, Wildman SA, Hruz PW.

J Biol Chem. 2014 Jun 6;289(23):16100-13. doi: 10.1074/jbc.M113.528430. Epub 2014 Apr 4.

36.

Epidemiology of eosinophilic esophagitis.

Hruz P.

Dig Dis. 2014;32(1-2):40-7. doi: 10.1159/000357008. Epub 2014 Feb 28. Review.

37.

Infliximab in the treatment of Crohn disease and type 1 diabetes.

Timper K, Hruz P, Beglinger C, Donath MY.

Diabetes Care. 2013 Jul;36(7):e90-1. doi: 10.2337/dc13-0199. No abstract available.

38.

Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy.

Vyas AK, Aerni-Flessner LB, Payne MA, Kovacs A, Jay PY, Hruz PW.

Cardiovasc Endocrinol. 2012 Dec;1(4):74-82.

39.

GLUT4, GLUT1, and GLUT8 are the dominant GLUT transcripts expressed in the murine left ventricle.

Aerni-Flessner L, Abi-Jaoude M, Koenig A, Payne M, Hruz PW.

Cardiovasc Diabetol. 2012 Jun 8;11:63. doi: 10.1186/1475-2840-11-63.

40.

Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland.

Hruz P, Straumann A, Bussmann C, Heer P, Simon HU, Zwahlen M, Beglinger C, Schoepfer AM; Swiss EoE study group.

J Allergy Clin Immunol. 2011 Dec;128(6):1349-1350.e5. doi: 10.1016/j.jaci.2011.09.013. Epub 2011 Oct 21. No abstract available.

PMID:
22019091
41.

Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.

Jenikova G, Hruz P, Andersson MK, Tejman-Yarden N, Ferreira PC, Andersen YS, Davids BJ, Gillin FD, Svärd SG, Curtiss R 3rd, Eckmann L.

Vaccine. 2011 Nov 28;29(51):9529-37. doi: 10.1016/j.vaccine.2011.09.126. Epub 2011 Oct 12.

42.
43.

Importance of Toll-like receptor 9 in host defense against M1T1 group A Streptococcus infections.

Zinkernagel AS, Hruz P, Uchiyama S, von Köckritz-Blickwede M, Schuepbach RA, Hayashi T, Carson DA, Nizet V.

J Innate Immun. 2012;4(2):213-8. doi: 10.1159/000329550. Epub 2011 Aug 19.

44.

Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes.

Remedi MS, Agapova SE, Vyas AK, Hruz PW, Nichols CG.

Diabetes. 2011 Oct;60(10):2515-22. doi: 10.2337/db11-0538. Epub 2011 Aug 3.

45.

Molecular mechanisms for insulin resistance in treated HIV-infection.

Hruz PW.

Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):459-68. doi: 10.1016/j.beem.2010.10.017. Review.

46.

Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy.

Vyas AK, Yang KC, Woo D, Tzekov A, Kovacs A, Jay PY, Hruz PW.

PLoS One. 2011 Feb 17;6(2):e17178. doi: 10.1371/journal.pone.0017178.

47.

GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy-rodent model system.

Hruz PW, Yan Q, Tsai L, Koster J, Xu L, Cihlar T, Callebaut C.

Antimicrob Agents Chemother. 2011 Apr;55(4):1377-82. doi: 10.1128/AAC.01184-10. Epub 2011 Jan 18.

48.

Innate immune defence: NOD2 and autophagy in the pathogenesis of Crohn's disease.

Hruz P, Eckmann L.

Swiss Med Wkly. 2010 Dec 27;140:w13135. doi: 10.4414/smw.2010.13135. eCollection 2010. Review.

49.

Liver regeneration is impaired in lipodystrophic fatty liver dystrophy mice.

Gazit V, Weymann A, Hartman E, Finck BN, Hruz PW, Tzekov A, Rudnick DA.

Hepatology. 2010 Dec;52(6):2109-17. doi: 10.1002/hep.23920. Epub 2010 Oct 21.

50.

Effects of the HIV protease inhibitor ritonavir on GLUT4 knock-out mice.

Vyas AK, Koster JC, Tzekov A, Hruz PW.

J Biol Chem. 2010 Nov 19;285(47):36395-400. doi: 10.1074/jbc.M110.176321. Epub 2010 Sep 23.

Supplemental Content

Support Center